🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11739086

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

Aclaris Therapeutics, Inc. · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11731986

Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11732005

Peptidomimetic proteasome inhibitors

Tri-Institutional Therapeutics Discovery Institute, Inc. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11731968

Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preven

HEPAREGENIX GMBH · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730720

ALK5 inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11725008

Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

The Board of Regents of the University of Texas System · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718612

Inhibitors of receptor interacting protein kinase I for the treatment of disease

The Board of Regents of the University of Texas System · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718618

Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Neurocrine Biosciences, Inc. · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718613

N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11712460

Methods of treating chronic disorders with complement inhibitors

Apellis Pharmaceuticals, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713313

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713315

5 to 7 membered heterocyclic amides as JAK inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713461

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708364

Azaindole derivatives and their use as ERK kinase inhibitors

AGV Discovery · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708333

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708329

Inhibitors of the WNT/beta-catenin pathway

The Regents of the University of California · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708332

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11708347

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701361

p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an

The Regents of the University of Colorado · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11702400

Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kina

Medshine Discovery Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11702411

Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

Revolution Medicines, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701354

Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

Relay Therapeutics, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11702389

Piperidine derivatives as HDAC1/2 inhibitors

Regenacy Pharmaceuticals, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11697648

Fused pyrimidine pyridinone compounds as JAK inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted